Solvay Pharmaceuticals, Gmbh

Kali-chemie Pharma Gmbh

Abbott Products Gmbh

Abbott Healthcare Products B.v.

Michael Mlinaric

Dieter Ziegler

Reinhard Brueckner

Michael Weske

Yvan Fischer

Klaus Witte

Brian Moloney

Lester Marrison

Christiane Boecker

Wolfgang Kehrbach

Willi Bielenberg

David Sykes

Josephus H M Lange

Konrad Koehler

Pieter Smid

Sara Nuñez Garcia

Elmar Wegener

This invention concerns spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein R, R, (R), and (R)have the meanings given in the specification.

Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers

Compounds corresponding to formula I, wherein R, R, R, R, R, R, R, R, R, Rand n have the meanings given in the description, and also a process for the preparation of these compounds and intermediate products of this process. Furthermore, pharmaceutical compositions comprising the compounds of Formula I and related methods of treatment.

[object Object]

The use of compounds corresponding to formula I: in which R, R, R, R, Rand Rhave the meanings given in the description for treating cardiac arrhythmias and other disease states.

Compounds corresponding to formula I: in which R, R, R, R, Rand Rhave the meanings given in the description; a process for the preparation of these compounds; intermediate products used to prepare such compounds, and pharmaceutical compositions containing such compounds.

Amidomethyl-substituted 2-(4-sulfonylamino)-3-hydroxy-3,4-dihydro-2H-chromen-6-yl compounds, a process and intermediates for their production, and pharmaceutical compositions containing them

3-(Phenylalkylaminoalkyloxy)-heteroaryl compounds having heart rate lowering and/or anti-ischemic effects, methods for their preparation and pharmaceutical compositions containing them are described. The compounds correspond to the general formula I ##STR1## or to the general formula XXXI ##STR2## in which the substituents have the meanings given in the specification.

(Phenylalkylaminoalkyloxy) -heteroaryl-compounds, processes and

3-(Phenylalkylaminoalkylozy)-heteroaryl compounds having heart rate lowering and/or anti-ischemic effects, methods for their preparation and pharmaceutical compositions containing them are described. The compounds correspond to the general formula I ##STR1## or to the general formula XXXI ##STR2## in which the substituents have the meanings given the specification.

(Phenylalkylaminoalkyloxy)-heteroaryl-compounds, processes and

Growing community of inventors

Hannover, Germany

Michael Mlinaric